Plasminogen and plasmin activity in patients with coronary artery disease

Journal of Thrombosis and Haemostasis

Volumn 4, Issue 6, 2006, Pages 1288-1295

  Drinane, M C ^a   Sherman, J A ^a   Hall, A E ^a   Simons, M ^a   Mulligan Kehoe, Mary Jo ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

Coronary artery disease; Plasmin; Plasminogen

Indexed keywords

PLASMIN; PLASMINOGEN; PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; EPITOPE MAPPING; FEEDBACK SYSTEM; FEMALE; FIBRINOLYSIS; HUMAN; HYPOTHESIS; KRINGLE DOMAIN; MALE; MOLECULAR INTERACTION; PRIORITY JOURNAL; PROTEIN CONFORMATION; REGULATORY MECHANISM;

ADOLESCENT; ADULT; CORONARY ARTERY DISEASE; EPITOPE MAPPING; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HUMANS; KRINGLES; MALE; PLASMA; PLASMIN; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN BINDING; TISSUE PLASMINOGEN ACTIVATOR; URINARY PLASMINOGEN ACTIVATOR;

EID: 33646784329     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2006.01979.x     Document Type: Article

References (22)

1. Ponting CP, Marshall JM, Cederhom-Williams SA. Plasminogen: A structural review. Blood Coagul Fibrinolysis 1992; 3: 605-14.
2. Robbins KC, Summaria L, Hsieh B, Shah RJ. Mechanism of activation of human plasminogen to plasmin. J Biol Chem 1967; 242: 2333-42.
3. Cockell CS, Marshall JM, Dawson KM, Cederholm-Williams SA, Ponting CP. Evidence that the conformation of unliganded human plasminogen is maintained via an intramolecular interaction between the lysine-binding site of kringle 5 and the N-terminal peptide. Biochem J 1998; 333: 99-105.
4. Violand BN, Castellino FJ. Mechanism of the urokinase-catalyzed activation of human plasminogen. J Biol Chem 1976; 251: 3906-12.
5. Wiman B. Primary structure of peptides released during activation of human plasminogen by urokinase. Eur J Biochem 1973; 39: 1-9.
6. Wiman B, Wallen P. Activation of human plasminogen by an insoluble derivative of urokinase. Structural changes of plasminogen in the course of activation to plasmin and demonstration of a possible intermediate compound. Eur J Biochem 1973; 36: 25-31.
7. Hoylaerts M, Rijken DC, Lijnen HR, Collen D. Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. J Biol Chem 1982; 257: 2912-9.
8. Soff GA. Angiostatin and angiostatin-related proteins. Cancer Metastasis Rev 2000; 19: 97-107.
9. Lijnen HR. Pleiotropic functions of plasminogen activator inhibitor-1. J Thromb Haemost 2005; 3: 35-45.
10. Alfano D, Franco P, Vocca I, Gambi N, Pisa V, Mancini A, Caputi M, Carriero MV, Iaccarino I, Stoppelli MP. The urokinase plasminogen activator and its receptor: Role in cell Growth and apoptosis. Thromb Haemost 2005; 93: 205-11.
11. Stump DC, Lijnen HR, Collen D. Purification and characterization of a novel low molecular weight form of single-chain urokinase-type plasminogen activator. J Biol Chem 1986; 261: 17120-6.
12. Dobrovolsky AB, Titaeva EV. The fibrinolysis system: Regulation of activity and physiologic functions of its main components. Biochemistry 2002; 67: 99-108.
13. Collen D. On the regulation and control of fibrinolysis. Thromb Haemost 1980; 43: 77-89.
14. Stack MS, Gately S, Bafetti LM, Enghild JJ, Soff GA. Angiostatin inhibits endothelial and melanoma cellular invasion by blocking matrix-enhanced plasminogen activation. Biochem J 1999; 340: 77-84.
15. Oger E, Leroyer C, Bressollette LM, Nonent M, Le Moigne E, Bizais Y, Amiral J, Grimaux M, Clavier J, Ill P, Abgrall JF, Mottier D. Evaluation of a new, rapid, and quantitative D-Dimer test in patients with suspected pulmonary embolism. Am J Respir Crit Care Med 1998; 158: 65-70.
16. Borries M, Heins M, Fischer Y, Stiegler H, Peters A, Reinauer H, Schoebel FC, Strauer BE, Leschke M. Changes of hemostasis, endogenous fibrinolysis, platelet activation and endothelins after percutaneous transluminal coronary angioplasty in patients with stable angina. J Am Coll Cardiol 1999; 34: 486-93.
17. Davi G, Violi F, Catalano I, Giammarresi C, Putignano E, Nicolosi G, Barbagallo M, Notarbartolo A. Increased plasminogen activator inhibitor antigen levels in diabetic patients with stable angina. Blood Coagul Fibrinolysis 1991; 2: 41-5.
18. de Maat MP, de Bart AC, Hennis BC, Meijer P, Havelaar AC, Mulder PG, Kluft C. Interindividual and intraindividual variability in plasma fibrinogen, tPA antigen, PAI activity, and CRP in healthy, young volunteers and patients with angina pectoris. Arterioscler Thromb Vasc Biol 1996; 16: 1156-62.
19. Lowe GD, Danesh J, Lewington S, Walker M, Lennon L, Thomson A, Rumley A, Whincup PH. Tissue plasminogen activator antigen and coronary heart disease. Prospective study and meta-analysis. Eur Heart J 2004; 25: 252-9.
20. Smith FB, Fowkes FG, Rumley A, Lee AJ, Lowe GD, Hau CM. Tissue plasminogen activator and leucocyte elastase as predictors of cardiovascular events in subjects with angina pectoris: Edinburgh Artery Study. Eur Heart J 2000; 21: 1607-13.
21. Yazdani S, Simon AD, Kovar L, Wang W, Schwartz A, Rabbani LE. Percutaneous interventions alter the haemostatic profile of patients with unstable versus stable angina. J Am Coll Cardiol 1997; 30: 1284-7.
22. Paramo JA, Orbe J, Fernandez J. Fibrinolysis/proteolysis balance in stable angina pectoris in relation to angiographic findings. Thromb Haemost 2001; 86: 636-9.